Remarks by: Scott Serota, President and Chief Executive Officer, Blue Cross Blue Shield Association
Introduction by: Bruce Gottlieb, President, National Journal Group
Moderator: Marilyn Werber Serafini, Communications Director & Health Policy Advisor, Alliance for Health Reform
Kirsten Axelsen, Vice President for Worldwide Policy & Public Affairs, Pfizer Inc.
Jean Johnson, Ph.D., FAAN, Chair of the Board, Nurse Practitioner Healthcare Foundation (NPHF); Dean, the George Washington University School of Nursing
Jennifer Lee, Board Member, Arlington Free Clinic
Elissa Passiment, Executive Vice President, American Society for Clinical Laboratory Science
Thomas Priselac, President and Chief Executive Officer, Cedars-Sinai Medical Center
John R. Seffrin, PhD, Chief Executive Officer, American Cancer Society
Kirsten Axelsen began her career at Pfizer in 2000 in New York Headquarters and has assumed positions of increasing responsibility in public affairs and policy, as well as in management science. As a vice president in worldwide policy and in public affairs, Ms. Axelsen leads a team responsible for analyzing how changes in government policy affect Pfizer as well as healthcare providers and their patients and then developing business guidance and strategic recommendations based on that analysis. Ms. Axelsen has published studies on medication adherence and the effect of co-pay and access restrictions on utilization of prescription drugs and other healthcare services.
Bruce Gottlieb is president of the National Journal Group, which publishes National Journal, National Journal Daily, National Journal Hotline, and other publications. He also serves as the general counsel of Atlantic Media Company, which publishes The Atlantic, Quartz, and Government Executive. Before joining Atlantic Media, he was chief counsel of the Federal Communications Commission, responsible for managing the agency’s overall policy agenda, and a senior advisor to Chairman Julius Genachowski. He was formerly a staff writer for Slate, where he was the first author of the Explainer column, and he has written for publications including The Atlantic, The New York Times Magazine, and The New Republic. He is a magna cum laude graduate of Harvard College and of Harvard Law School and began his legal career as a clerk for Judge David S. Tatel of the Court of Appeals for the District of Columbia Circuit.
Dr. Jean Johnson is dean and professor of the School of Nursing at The George Washington University. She is responsible for all aspects of the school and provided leadership in the establishment of the SON by the Board of Trustees in May 2010. Prior to serving as dean, Dr. Johnson was senior associate dean for the Health Sciences Programs. She was also the national program director for a $20 million dollar project to take primary care educational programs into underserved areas national-wide. In addition, Dr. Johnson has worked internationally on nursing issues in Saudi Arabia, Eritrea and South Africa.
Jennifer Lee is a volunteer physician and board member at the Arlington Free Clinic in Arlington, Virginia, where she has been helping the clinic understand and respond to the implications of health reform for the clinic.
She currently works as the special assistant for community engagement to the Principal Deputy Under Secretary for Health in the Veterans Health Administration. Prior to that, Dr. Lee served as a White House Fellow in the Department of Veterans Affairs.
Dr. Lee holds a faculty appointment in the Departments of Emergency Medicine and Health Policy at The George Washington University. She completed her residency training in emergency medicine at Johns Hopkins University and received her medical degree from the Washington University School of Medicine and her undergraduate degree from Yale University. She was a health policy fellow on the US Senate Health, Education, Labor, and Pensions Committee from 2002- 2003.
From 2010-11, she served as co-chair of the Northern Virginia Access to Health Care Consortium. She was appointed by Governor Tim Kaine to serve on the Virginia Board of Medicine from 2008-11.
Elissa Passiment is the executive vice president of the American Society for Clinical Laboratory Science (ASCLS). She is also an adjunct assistant professor in the School of Health Related Professions at the University of Medicine and Dentistry. She is a clinical laboratory scientist with over twenty years’ experience in clinical laboratories as staff, educator and manager and twenty years in health care consulting and policy. Ms. Passiment came to ASCLS after six years in health care consulting with an international health care firm.
She has also been active as a member of ASCLS, serving on numerous national committees, its Board of Directors and as President in 1988-89. She has served on the congressionally mandated Negotiated Rulemaking Committee convened to standardize and simplify reimbursement for laboratory services under Medicare Part B; presented testimony to Institute of Medicine studies, and represents ASCLS at meetings with the FDA, CMS, and CDC.
Thomas M. Priselac is president and chief executive officer of the Cedars-Sinai Health System -- a position he has held since January 1994. Mr. Priselac has been associated with Cedars-Sinai since 1979. Prior to being named president and chief executive officer, he was executive vice president from 1988 to 1993. Before joining Cedars-Sinai, he was on the executive staff of Montefiore Hospital in Pittsburgh. Additionally, he is a past chair of the American Hospital Association Board of Trustees and a past chair of the Association of American Medical Colleges.
John R. Seffrin
John Seffrin, Ph.D. has been chief executive officer of the American Cancer Society since 1992. Under his leadership, the Society has become the world’s largest voluntary health organization fighting cancer, with a billion dollars in resources to save lives by helping people stay well and get well, by finding cures, and by fighting back. He spearheaded the creation of the Society’s nonprofit, nonpartisan advocacy affiliate, the American Cancer Society Cancer Action NetworkSM, of which he is also the chief executive officer.
He currently serves on the White House Advisory Group on Prevention, Health Promotion, and Integrative and Public Health, as well as the Advisory Committee to the Director of the U.S. Centers for Disease Control and Prevention, a Secretary-level appointment.
Scott Serota is president and chief executive officer of the Blue Cross and Blue Shield Association (BCBSA), a national federation of 37 independent, community-based and locally operated Blue Cross and Blue Shield companies. The Blue System is the nation's largest health insurer covering 100 million people – one-in-three of all Americans.
Mr. Serota was named BCBSA president and chief executive officer in 2000, after serving four years as a senior executive, including two years as chief operating officer. Before that, he was executive vice president for system development, responsible for new business, strategy and the Blue Technology Evaluation Center, the nation’s leading source for evaluating the safety and efficacy of emerging medical treatments.
Prior to joining the Blues, Mr. Serota was president and chief executive officer of Chicago-based Rush Prudential Health Plans, where he led the integration of Rush-Presbyterian-St. Luke’s Medical Center Health Plans and The Prudential. Earlier in his career, Mr. Serota also created and led Physicians Preferred Health Inc., a Missouri-based PHO.
Marilyn Werber Serafini
Before joining the Alliance, Marilyn Werber Serafini was the Robin Toner Distinguished Fellow and senior correspondent at Kaiser Health News. She was an award-winning health care and welfare correspondent for National Journal magazine from 1995 to 2010, and before that was a senior reporter for CongressDaily (now National Journal Daily). She holds a master’s degree in journalism and public affairs from American University and an undergraduate degree from the University of Maryland.
John Seffrin, CEO of the American Cancer Society, explains how the Affordable Care Act and its insurance policy for patients with pre-existing conditions will give cancer patients 'access to survivor-ship.'